News - 3 Feb 2009
Mirna Therapeutics ("Mirna"), a wholly owned subsidiary of Asuragen, Inc. and the University of California, San Francisco announce that they have entered into a collaboration agreement to...
News - 23 Oct 2008
Tekmira Pharmaceuticals Corporation announced today that studies conducted by Tekmira and Johnson + Johnson Pharmaceutical Research + Development, Division of Janssen Pharmaceutica, N.V., have shown...
News - 15 Nov 2007
Altair Nanotechnologies Inc. announced today that the recently passed Defense Appropriations Bill signed into law by President Bush on November 12, 2007, provides for $7 million in federal funding...
Article - 23 Aug 2019
This article discusses nanorobotics in the biomedical industry and their applications.
Article - 28 May 2015
Oil spills resulting from fuel transportation and drilling operation have a great impact on the environment besides causing a huge loss of energy resources. It is necessary to take an appropriate...
Article - 29 Mar 2013
Nanoparticles are significant scientific tools that are being explored in various technological and pharmacological fields. They are a link between larger materials and molecular or atomic structures....
Article - 28 Jun 2005
Research in the field of nanobiotechnology could help to improve the ways in which cancer is detected and treated. Medical imaging, labeling methods, quantum dots, nanosensors, lab on a chip devices,...
News - 30 Oct 2015
Celator Pharmaceuticals, Inc. today announced that data from applying the CombiPlex® technology platform to drug combinations incorporating molecularly targeted agents (MTAs) will be presented at...
News - 22 Sep 2015
CeloNova BioSciences, Inc. (CeloNova) announced today that it has received conditional approval to start an investigational device exemption (IDE) trial to study the COBRA PzF coronary stent system in...
News - 22 Jan 2015
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has dosed the first subject in a Phase I clinical trial of TKM-HBV, a...